Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

NCT01102231 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT01102231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01102231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
December 31, 2015
Enrollment
106 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii non-small cell lung cancer